Australia Women’s Health Market Size & Outlook, 2023-2030
Australia women’s health market, 2018-2030 (US$M)
Related Markets
Australia women’s health market highlights
- The Australia women’s health market generated a revenue of USD 933.8 million in 2023 and is expected to reach USD 1,634.9 million by 2030.
- The Australia market is expected to grow at a CAGR of 8.3% from 2024 to 2030.
- In terms of segment, contraceptives was the largest revenue generating application in 2023.
- Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.
Women’s health market data book summary
| Market revenue in 2023 | USD 933.8 million |
| Market revenue in 2030 | USD 1,634.9 million |
| Growth rate | 8.3% (CAGR from 2023 to 2030) |
| Largest segment | Contraceptives |
| Fastest growing segment | Endometriosis & Uterine Fibroids |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, Australia accounted for 2.1% of the global women’s health market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan women’s health market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 3,966.1 million by 2030.
Contraceptives was the largest segment with a revenue share of 32.11% in 2023. Horizon Databook has segmented the Australia women’s health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.
According to the Fertility Society of Australia and New Zealand, every sixth couple has trouble becoming pregnant. Problems with fertility can be brought on by illnesses and other conditions. Overall, female reproductive difficulties account for one-third of infertility cases.
Such factors are expected to boost market growth. Moreover, players in the country are adopting various strategies to expand their market presence and meet consumer demand. For instance, in July 2022, Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA announced the availability of NEXTSTELLIS, an oral contraceptive with a novel estrogen in Australia.
Similarly, in October 2021, Slinda, a contraceptive pill manufactured by Exeltis, became available in Australia. Moreover, favorable initiatives undertaken by government bodies to consume contraceptive pills are expected to drive the market.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Women’s Health Market Scope
Women’s Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia women’s health market size, by application, 2018-2030 (US$M)
Australia Women’s Health Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
